Plaintiff
7 cases as plaintiff.
Neurent Medical Ltd is a privately held MedTech company headquartered in Galway, Ireland, with U.S. operations in Braintree, Massachusetts. Founded in 2015 by David Townley and Brian Shields, the company employs approximately 35 to 76 individuals and is venture-backed. Neurent Medical has raised substantial funding, including a €62.5 million ($74 million) Series C financing round in February 2026.
The company specializes in developing innovative treatments for chronic inflammatory sino-nasal diseases. Its primary product is the NEUROMARK® System, a minimally invasive device that utilizes proprietary Impedance Controlled Radiofrequency technology. This system is designed to precisely target and disrupt hyperactive posterior nasal nerves, providing relief from chronic rhinitis symptoms such as congestion, rhinorrhea, sneezing, and nasal itching. The NEUROMARK® System has received U.S. FDA clearance for its next-generation device and has a dedicated CPT code for reimbursement.
Neurent Medical demonstrates an active two-way patent litigation posture. The company has appeared as a plaintiff in one tracked case, Neurent Medical Ltd. v. Aerin Medical Inc. in the U.S. District Court for the District of Delaware, filed in September 2024. Simultaneously, it has been a defendant in one case, Unified Patents v. Neurent Medical Ltd, before the Patent Trial and Appeal Board (PTAB). This indicates that Neurent Medical is both asserting its patent rights and defending them against challenges.
Watchlist
Email-only, free, anonymous. We'll notify you when Neurent Medical Ltd. files another patent-infringement lawsuit. One-click unsubscribe from any alert.
This district court case involves Neurent Medical Ltd. suing Aerin Medical Inc. An oral argument on a motion to consolidate cases and stay was held, and the motion was granted-in-part, with parties ordered to prepare consolidation documents and a proposed interim schedule.
Neurent petitioned for inter partes review of the '077 patent. The Board granted Neurent's opposed motion to withdraw the petition and dismissed the proceeding prior to institution.
Neurent petitioned for inter partes review of all asserted claims of the '286 patent. The Board instituted review and issued a Final Written Decision on July 11, 2025, finding all challenged claims unpatentable as obvious; Aerin appealed.
Neurent Medical Inc. and Neurent Medical Ltd. filed an inter partes review challenging U.S. Patent No. 9,072,597. The Board instituted review on 2024-07-22; the proceeding terminated on 2025-01-24 by adverse judgment after Aerin statutorily disclaimed the '597 claims.
Neurent Medical Inc. and Neurent Medical Ltd. petitioned for inter partes review of US 9,415,194, challenging claims 1–3, 6, 12, 14, 16, 18, and 19. The PTAB instituted on July 22, 2024, and terminated by adverse judgment on January 24, 2025, after Aerin statutorily disclaimed the challenged claims.
Neurent Medical Inc. and Neurent Medical Ltd. filed an IPR challenging claims 1–3, 7, 9–10, and 17–25 of US 10,610,675 on four grounds. The PTAB issued a Final Written Decision on July 21, 2025.
Inter partes review petition by Neurent Medical Inc. and Neurent Medical Ltd. challenging claims 1–4, 6–12, and 16 of U.S. Patent 11,241,271. Institution was granted July 22, 2024, and the Final Written Decision of July 11, 2025 held the challenged claims unpatentable as obvious; the patent owner appealed.